亚宝药业(600351.SH)：SY-005项目新适应症获临床试验批准

Core Viewpoint - The company has received approval for a new clinical trial indication for its innovative recombinant protein SY-005, targeting neurological deficits after brain glioma surgery [1] Company Summary - The company, Yabao Pharmaceutical (600351.SH), announced that its subsidiary, Suzhou Yabao Pharmaceutical Research Co., Ltd., received a clinical trial approval notice from the National Medical Products Administration for SY-005 injection [1] - SY-005 is currently in the second phase of clinical trials for the treatment of sepsis, having received its initial clinical trial approval in November 2018 [1] - The newly approved indication for SY-005 is for neurological deficits following brain glioma surgery [1]